Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET
Company Participants
Paul Cox - Vice President, Investor Relations & Corporate Communications
Ryan Spencer - Chief Executive Officer
Donn Casale - Chief Commercial Officer
Rob Janssen - Chief Medical Officer
Kelly MacDonald - Chief Financial Officer
Conference Call Participants
Matthew Phipps - William Blair
Jonathan Miller - Evercore ISI
Paul Choi - Goldman Sachs
Ernesto Rodriguez-Dumont - Cowen
Roy Buchanan - Citizens JMP
Operator
Good day ladies and gentlemen and welcome to the Dynavax Technologies' Fourth Quarter and Full Year 2023 Financial Results Conference Call. As a reminder, this call is being recorded. At the end of the company's prepared remarks, we'll open the call for questions and provide specific instructions at that time.
I would now like to turn the call over to Paul Cox, Vice President, Investor Relations and Corporate Communications. You may begin.
Paul Cox
Thank you for participating in today's call. Joining me from Dynavax are Ryan Spencer, Chief Executive Officer; Donn Casale, Chief Commercial Officer; Rob Janssen, Chief Medical Officer; and Kelly MacDonald, Chief Financial Officer.
Earlier today, Dynavax released financial results for the fourth quarter and full year ended December 31st, 2023. Copies of the press release and a supplementary slide presentation are available on Dynavax's website.
Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to, potential market sizes, market segmentation, effective marketing efforts, future expected market share, and related growth rates, and related ACIP recommendation impact on each financial guidance and trends including revenue, profitability, cash flow, and sufficiency of current capitalization, timing and results of FDA submissions, clinical trial starts and data readouts, and potential future uses of order demand for our CpG 1018 adjuvant.
These statements involve risks and uncertainties and our actual results may differ materially. These risks are summarized in today's press release and detailed in the risk factors section of our SEC filings including today's Annual Report on Form 10 K. Our forward-looking statements speak as of today and we undertake no obligation to update such statements.
And with that, I will now turn the call over to Ryan.
Ryan Spencer
Thanks Paul. Good afternoon everyone and thank you for taking the time to join us to review Dynavax results for 2023. 2023 was characterized by record revenue growth for HEPLISAV-B, delivering 69% growth year-over-year, and becoming the market leader market share leader in the two largest growth segments, which are retail pharmacies and integrated delivery networks, making HEPLISAV-B the leading vaccine in the U.S. adult hepatitis B vaccine market.